PROLead story · #cash-secured-put
BMY: a Good lower-entry put, with clinical-news risk
Bristol Myers Squibb’s revenue outlook supports a lower-entry put, but mixed trend, reduced EPS guidance and imminent ASH news keep the rating at Good. Full setup and exit plan inside.









